Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 1496 | 2.28 |
09:34 ET | 800 | 2.26 |
09:36 ET | 881 | 2.252 |
09:41 ET | 400 | 2.26 |
09:50 ET | 790 | 2.24 |
09:54 ET | 100 | 2.24 |
09:56 ET | 100 | 2.235 |
09:57 ET | 1457 | 2.2208 |
10:01 ET | 3158 | 2.24 |
10:03 ET | 779 | 2.245 |
10:06 ET | 2342 | 2.24 |
10:10 ET | 6306 | 2.225 |
10:12 ET | 100 | 2.225 |
10:14 ET | 1100 | 2.23 |
10:15 ET | 1500 | 2.235 |
10:17 ET | 300 | 2.235 |
10:24 ET | 100 | 2.235 |
10:26 ET | 100 | 2.235 |
10:28 ET | 301 | 2.2308 |
10:32 ET | 1670 | 2.23 |
10:33 ET | 100 | 2.225 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 153.9M | -0.9x | --- |
Organogenesis Holdings Inc | 375.2M | -22.3x | --- |
Amarin Corporation PLC | 266.2M | -7.8x | --- |
Coherus BioSciences Inc | 154.4M | -3.4x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Puma Biotechnology Inc | 132.4M | 14.5x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $153.9M |
---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 0.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.